Novartis' plea for Glivec patent denied by Indian high court

04/1/2013 | Reuters

Western drugmakers suffered a major blow after the Indian Supreme Court rejected Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling sets a reference point for other intellectual-property disputes in the country and is likely to affect many other drugmakers and their brand-name treatments, analysts say.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR